PeptideDB

GSK251 2125968-05-8

GSK251 2125968-05-8

CAS No.: 2125968-05-8

GSK251 is a highly efficient, selective, orally bioavailable PI3Kδ inhibitor (antagonist) with a novel binding mode.
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

GSK251 is a highly efficient, selective, orally bioavailable PI3Kδ inhibitor (antagonist) with a novel binding mode.

Physicochemical Properties


Molecular Formula C29H37FN6O4S
Molecular Weight 584.71
Exact Mass 584.26
Elemental Analysis C, 59.57; H, 6.38; F, 3.25; N, 14.37; O, 10.94; S, 5.48
CAS # 2125968-05-8
PubChem CID 130302563
Appearance Off-white to light yellow solid powder
LogP 2.6
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 11
Rotatable Bond Count 9
Heavy Atom Count 41
Complexity 912
Defined Atom Stereocenter Count 0
InChi Key ODQVPYNCHSLNGV-UHFFFAOYSA-N
InChi Code

InChI=1S/C29H37FN6O4S/c1-21(2)35-10-8-34(9-11-35)20-22-4-5-25(26(30)16-22)27-17-23(6-7-31-27)33-41(37,38)28-18-24(19-32-29(28)39-3)36-12-14-40-15-13-36/h4-7,16-19,21H,8-15,20H2,1-3H3,(H,31,33)
Chemical Name

N-(2-(2-fluoro-4-((4-isopropylpiperazin-1-yl)methyl)phenyl)pyridin-4-yl)-2-methoxy-5-morpholinopyridine-3-sulfonamide
Synonyms

GSK251; GSK 251; GSK-251;
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


References

[1]. Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode. J Med Chem. 2021 Sep 23;64(18):13780-13792.


Solubility Data


Solubility (In Vitro) DMSO : ~62.5 mg/mL (~106.89 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.08 mg/mL (3.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.08 mg/mL (3.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.08 mg/mL (3.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.7102 mL 8.5512 mL 17.1025 mL
5 mM 0.3420 mL 1.7102 mL 3.4205 mL
10 mM 0.1710 mL 0.8551 mL 1.7102 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.